Trial Profile

Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma A University of California Hematologic Malignancies Consortium Protocol (UCHMC1809)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary) ; Pomalidomide (Primary)
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Acronyms UCHMC1809

29 May 2025 Planned End Date changed from 1 Oct 2025 to 1 Oct 2026.
29 May 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Mar 2026.
29 Apr 2024 Planned End Date changed from 1 Oct 2024 to 1 Oct 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com